DXCM

$68.20+1.86 (+2.80%)

Market OpenAs of Mar 17, 4:58 PM UTC

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$68.20
Potential Downside
23.7%
Whystock Fair Value$52.04
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$26.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
32.63
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
34.50%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.53

Recent News

StockStory
Mar 17, 2026

Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know

A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 16, 2026

Here's Why You Should Hold DexCom Stock in Your Portfolio for Now

DXCM gains from CGM demand, Medicare coverage expansion and its new G7 15-day sensor, but rising competition and manufacturing investments may pressure margins.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Mar 16, 2026

Is Dexcom (DXCM) Fairly Priced After Recent Share Price Pressure?

If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that price might actually represent for you. The stock has been under pressure recently, with returns of 6.5% over the last week, 8.3% over the past month, 3.5% year to date and 10.0% over the last year, and a 45.2% and 28.6% return over the past 3 and 5 years respectively. Recent coverage has focused on DexCom's position in continuous glucose monitoring and how sentiment...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement

This medical technology firm delivers advanced noninvasive monitoring and automation solutions to healthcare providers worldwide.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.